Who We Fund
Investments in Industry
ABC2’s investment provided the support Agios needed to move its cancer metabolism project into brain cancer. Prior to our involvement, Agios focused exclusively on leukemia research.
- Exosome Diagnostics
ABC2 and Exosome Diagnostics are collaborating with two leading academic research centers to accelerate the clinical validation of Exosome Diagnostic's biofluid-based diagnostic technology.
We are working with Novartis, Henry Ford Hospital, and Columbia University to develop state-of-the-art model systems to id
ABC2 funded Genentech’s early stage research and clinical trial work to test and develop the drug Avastin to treat brain cancer patients.
- Regulus Therapeutics
Regulus is now working with Samsung Medical Center to develop a microRNA therapeutic to target the “master control switches” in brain tumors.
ABC2 was the first non-profit organization to fund Tocagen, a biotech company that was able to then go onto raise additional funding for their groundbreaking therapy.
Brain Tumor Research Grants
We are funding the development of a clinical trial to determine if retinoic acid -- Accutane -- might be an effective brain cancer treatment for patients with IDH gene mutations.
- Johns Hopkins
We are funding a clinical trial at Johns Hopkins to test whether mebendazole, a drug already approved by the FDA to fight
- Mayo Clinic / T-Gen
ABC2’s investment helps move forward a novel personalized medicine trial for glioblastoma patients led by Mayo Clinic, one of the leading clinical centers, and TGen, a cutting edge genomics lab.
- UCSD & Regulus
Early detection of tumor recurrence remains one of the greatest challenges in the treatment of brain cancer.
ABC2 is funding a UCSF project to understand the effects of temozolomide on low-grade gliomas.
- University of Florida He
In collaboration with the Florida Center for Brain Tumor Research we have funded over $500,000 in brain cancer research in
ABC2’s investment and scientific guidance is helping to advance the work of an international consortium working on a treatment for a rare pediatric brain tumor called diffuse intrinsic pontine glioma (DIPG).
- Duke Medicine
This collaboration establishes a missing link between the biopharmaceutical industry’s efforts to produce life-saving drugs and theoretical knowledge at the cutting edge of scientific inquiry.